Combined dexamethasone and low-molecular-weight dextran in acute brain infarction: double-blind study.
Intramuscular dexamethasone combined with intravenous low-molecular-weight dextran (dextran 40) was compared with placebo in 40 patients with acute ischaemic cerebral infarction. A double-blind procedure was used. Dexamethasone was given for up to 14 days and dextran 40 for up to three days after the infarction. A weighted scoring system was used to evaluate neurological state and mobility. There were no differences in mortality or in improvement of the neurological or mobility scores between the two groups.
D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use*; D003911:Dextrans / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D009068:Movement; D009460:Neurologic Examination; D010919:Placebos
D003911:Dextrans; D010919:Placebos; D003907:Dexamethasone